{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:41:03Z","timestamp":1791474063262,"version":"4.3.4"},"reference-count":40,"publisher":"The Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Context: Prostate cancer (PCa) is the most common cancer in men. Androgen-deprivation therapy (ADT) is generally employed in the treatment of locally advanced and metastatic PCa. Although its use as an adjuvant therapy has resulted in improved survival in some patients, ADT has negative consequences. Complications like osteoporosis, sexual dysfunction, gynecomastia, and adverse body composition are well known. Recently, metabolic complications like insulin resistance, diabetes, dyslipidemia, and metabolic syndrome have emerged, which may be responsible for the increased cardiovascular mortality in this population.<\/jats:p>\n               <jats:p>Evidence Acquisition: A MEDLINE search was conducted for articles published over the last 20 yr based on the key words androgen deprivation therapy AND insulin resistance, hyperglycemia, diabetes, dyslipidemia, metabolic syndrome, and cardiovascular disease. Relevant studies in non-PCa populations evaluating the association between testosterone and metabolism were also reviewed and briefly mentioned where relevant.<\/jats:p>\n               <jats:p>Evidence Synthesis: Prospective studies evaluating early (3\u20136 months) metabolic changes of ADT show development of hyperinsulinemia; however, glucose levels remain normal. Cross-sectional studies of men undergoing long-term (\u226512 months) ADT reveal higher prevalence of diabetes and metabolic syndrome compared with controls. Furthermore, men undergoing ADT also experience higher cardiovascular mortality.<\/jats:p>\n               <jats:p>Conclusion: Long-term prospective studies of ADT are needed to determine the timing of onset of these metabolic complications and to investigate the mechanism behind them. In the meantime, we recommend baseline and serial screening for fasting glucose, lipids, and other cardiovascular risk factors in men receiving ADT. Glucose tolerance tests and cardiac evaluation may be required in selected cases.<\/jats:p>","DOI":"10.1210\/jc.2007-2595","type":"journal-article","created":{"date-parts":[[2008,3,19]],"date-time":"2008-03-19T00:44:46Z","timestamp":1205887486000},"page":"2042-2049","source":"Crossref","is-referenced-by-count":143,"title":["Androgen Deprivation Therapy in Prostate Cancer and Metabolic Risk for Atherosclerosis"],"prefix":"10.1210","volume":"93","author":[{"given":"Sadeka","family":"Shahani","sequence":"first","affiliation":[{"name":"Department of Internal Medicine (S.S.), Harbor Hospital of Baltimore, Baltimore, Maryland 21225"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Braga-Basaria","sequence":"additional","affiliation":[{"name":"Department of Consultant Endocrinologist (M.B.-B.), Baltimore, Maryland 21209"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehzad","family":"Basaria","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism and Oncology (S.B.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21224"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071614240904400_R1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer statistics, 2007.","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"2020071614240904400_R2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archsurg.1941.01210140043004","article-title":"Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland.","volume":"43","author":"Huggins","year":"1941","journal-title":"Arch Surg"},{"key":"2020071614240904400_R3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/MED.0b013e32814db88c","article-title":"Androgen deprivation therapy for prostate cancer: new concepts and concerns.","volume":"14","author":"Smith","year":"2007","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2020071614240904400_R4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0090-4295(02)01677-1","article-title":"Critical evaluation of hormonal therapy for carcinoma of the prostate.","volume":"60","author":"Chodak","year":"2002","journal-title":"Urology"},{"key":"2020071614240904400_R5","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJM199912093412401","article-title":"Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.","volume":"341","author":"Messing","year":"1999","journal-title":"N Engl J Med"},{"key":"2020071614240904400_R6","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer.","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"key":"2020071614240904400_R7","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jama.280.11.1008","article-title":"Comparing treatments for localized prostate cancer: persisting uncertainty.","volume":"280","author":"Chodak","year":"1998","journal-title":"JAMA"},{"key":"2020071614240904400_R8","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/cncr.20955","article-title":"Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma.","volume":"103","author":"Shahinian","year":"2005","journal-title":"Cancer"},{"key":"2020071614240904400_R9","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1200\/JCO.1999.17.11.3461","article-title":"Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.","volume":"17","author":"Bubley","year":"1999","journal-title":"J Clin Oncol"},{"key":"2020071614240904400_R10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0002-9343(01)00663-5","article-title":"Hypogonadism and androgen replacement therapy in elderly men","volume":"110","author":"Basaria","year":"2001","journal-title":"Am J Med."},{"key":"2020071614240904400_R11","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/oxfordjournals.aje.a008832","article-title":"Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial.","volume":"143","author":"Haffner","year":"1996","journal-title":"Am J Epidemiol"},{"key":"2020071614240904400_R12","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1210\/jc.2004-1158","article-title":"Endogenous sex hormones and metabolic syndrome in aging men.","volume":"90","author":"Muller","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614240904400_R13","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1180::AID-CNCR18>3.0.CO;2-1","article-title":"Cause of death in men diagnosed with prostate carcinoma.","volume":"83","author":"Satariano","year":"1998","journal-title":"Cancer"},{"key":"2020071614240904400_R14","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.ju.0000127740.96006.1a","article-title":"Changing patterns in competing causes of death in men with prostate cancer: a population based study.","volume":"171","author":"Lu-Yao","year":"2004","journal-title":"J Urol"},{"key":"2020071614240904400_R15","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1210\/jcem.86.11.7983","article-title":"Anabolic-androgenic steroid therapy in the treatment of chronic diseases.","volume":"86","author":"Basaria","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614240904400_R16","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2265.2002.01551.x","article-title":"Long-term effects of androgen deprivation therapy in prostate cancer patients.","volume":"56","author":"Basaria","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071614240904400_R17","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1210\/jcem.86.9.7851","article-title":"The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer.","volume":"86","author":"Smith","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614240904400_R18","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/jcem.87.2.8299","article-title":"Changes in body composition during androgen deprivation therapy for prostate cancer.","volume":"87","author":"Smith","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614240904400_R19","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/cncr.10967","article-title":"Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.","volume":"95","author":"Chen","year":"2002","journal-title":"Cancer"},{"key":"2020071614240904400_R20","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/cncr.21381","article-title":"Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma.","volume":"104","author":"Lee","year":"2005","journal-title":"Cancer"},{"key":"2020071614240904400_R21","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0026-0495(94)90202-X","article-title":"Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men.","volume":"43","author":"Haffner","year":"1994","journal-title":"Metabolism"},{"key":"2020071614240904400_R22","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.2337\/diacare.27.5.1036","article-title":"Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men.","volume":"27","author":"Laaksonen","year":"2004","journal-title":"Diabetes Care"},{"key":"2020071614240904400_R23","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1210\/jc.2004-2190","article-title":"Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men.","volume":"90","author":"Pitteloud","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614240904400_R24","first-page":"991","article-title":"The effects of testosterone treatment on body composition and metabolism in middle-aged obese men.","volume":"16","author":"Marin","year":"1992","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2020071614240904400_R25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1042\/cs1040195","article-title":"Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia.","volume":"104","author":"Dockery","year":"2003","journal-title":"Clin Sci (Lond)"},{"key":"2020071614240904400_R26","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1210\/jc.2005-2507","article-title":"Insulin sensitivity during combined androgen blockade for prostate cancer.","volume":"91","author":"Smith","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614240904400_R27","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.21642","article-title":"Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen deprivation therapy.","volume":"106","author":"Basaria","year":"2006","journal-title":"Cancer"},{"key":"2020071614240904400_R28","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"2020071614240904400_R29","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1200\/jco.2004.22.14_suppl.4578","article-title":"The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix","volume":"22","author":"Garnick","year":"2004","journal-title":"J Clin Oncol"},{"key":"2020071614240904400_R30","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1191\/0961203304lu1094oa","article-title":"Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity.","volume":"13","author":"Cutolo","year":"2004","journal-title":"Lupus"},{"key":"2020071614240904400_R31","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2337\/diab.43.11.1271","article-title":"Tumor necrosis factor \u03b1: a key component of the obesity-diabetes link.","volume":"43","author":"Hotamisligil","year":"1994","journal-title":"Diabetes"},{"key":"2020071614240904400_R32","first-page":"2486","article-title":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).","volume-title":"JAMA","author":"Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults","year":"2001"},{"key":"2020071614240904400_R33","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","article-title":"Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.","volume":"24","author":"Braga-Basaria","year":"2006","journal-title":"J Clin Oncol"},{"key":"2020071614240904400_R34","first-page":"1610","article-title":"Relationship of sex hormones to lipids and lipoproteins in nondiabetic men.","volume":"77","author":"Haffner","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614240904400_R35","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2003-031069","article-title":"The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men.","volume":"89","author":"Malkin","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614240904400_R36","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1210\/jcem-66-2-314","article-title":"Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide.","volume":"66","author":"Moorjani","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614240904400_R37","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/sj.ijir.3901471","article-title":"Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy.","volume":"18","author":"Braga-Basaria","year":"2006","journal-title":"Int J Impot Res"},{"key":"2020071614240904400_R38","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.","volume":"110","author":"Saigal","year":"2007","journal-title":"Cancer"},{"key":"2020071614240904400_R39","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1200\/JCO.2006.09.3369","article-title":"Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.","volume":"25","author":"D'Amico","year":"2007","journal-title":"J Clin Oncol"},{"key":"2020071614240904400_R40","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","article-title":"Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.","volume":"99","author":"Tsai","year":"2007","journal-title":"J Natl Cancer Inst"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/93\/6\/2042\/9055338\/jcem2042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/93\/6\/2042\/9055338\/jcem2042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T02:12:07Z","timestamp":1594951927000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/93\/6\/2042\/2598172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6,1]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2007-2595","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6,1]]}}}